2-(2-bromophenylamino)-5-(4-fluorophenyl)-1,3,4-thiadiazole

2-(2-bromophenylamino)-5-(4-fluorophenyl)-1,3,4-thiadiazole is an experimental small molecule designed as a nonsteroidal aromatase inhibitor. It belongs to a class of 1,3,4-thiadiazole derivatives characterized by halogen-substituted aromatic rings. The compound demonstrates selective cytotoxic activity against estrogen-dependent breast cancer cells, such as the MCF-7 line, while showing minimal activity against estrogen-independent cells like MDA-MB-231. Its mechanism of action involves binding to the aromatase enzyme, which is responsible for the rate-limiting step in estrogen biosynthesis, thereby reducing estrogen levels that fuel tumor growth. Molecular modeling indicates that it occupies the same catalytic site as native aromatase inhibitors, suggesting its potential as a scaffold for developing targeted therapies for hormone-dependent malignancies.